EichorEICHOR
Study identifier: NCT05711940 Synced from ClinicalTrials.gov · August 04, 2026
● Active Not Recruiting

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Condition: Treatment Resistant Depression  ·  Sponsor: COMPASS Pathways

PhasePhase 3
Planned participants572
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

This description comes directly from the study's public registry record.

Talk to the study team

No contact information is available for this study as per the public registry record.

Always discuss trial participation with your own doctor first.

Locations (116)

Lighthouse Psychiatry ScottsdaleGilbert, Arizona, United States
Clinical Innovations, Inc.Bellflower, California, United States
M3 Wake ResearchEncino, California, United States
The Regents of the University of California - San DiegoLa Jolla, California, United States
Kadima Neuropsychiatry InstituteLa Jolla, California, United States
CalNeuro Research Group, IncLos Angeles, California, United States
Catalina Research Institute, LLCMontclair, California, United States
Piedmont Hospital Neuroscience CentreOakland, California, United States
ATP Clinical Research, Inc.Orange, California, United States
CITrialsRiverside, California, United States
Lumos Clinical Research CenterSan Jose, California, United States
Syrentis Clinical ResearchSanta Ana, California, United States

+ 104 more locations — full list on the registry record.

Follow this study

Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.

We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →